scispace - formally typeset
P

Philippe Rochigneux

Researcher at Aix-Marseille University

Publications -  43
Citations -  564

Philippe Rochigneux is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 28 publications receiving 330 citations. Previous affiliations of Philippe Rochigneux include University of California, Los Angeles & University Hospital of Lausanne.

Papers
More filters
Journal ArticleDOI

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.

TL;DR: In this review, the results of the most recent studies evaluating immune checkpoint inhibitors in breast cancer are reported and the concomitant development of possible biomarkers, which is required for improving the selection of patients with the highest probability of benefiting from these agents are discussed.
Journal ArticleDOI

Use of chemotherapy near the end of life: what factors matter?

TL;DR: Among hospitalized patients with cancer, young individuals, treated in comprehensive cancer centers or in high-volume centers without palliative care units were the most likely to receive chemotherapy near the end of life, and there was no obvious pattern between the expected chemosensitivity of different cancers and the rates of chemotherapy use close to death.
Journal ArticleDOI

Hospital end-of-life care in haematological malignancies

TL;DR: A high proportion of patients who died from haematological malignancies receive specific treatments near the end of life, suggesting a need for a better and earlier integration of the palliative care approach in the standard practice of haem atology.
Journal ArticleDOI

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials.

TL;DR: This review explains the concept of TCR modified and CAR-T cells in liver cancer (targets and mechanisms of action) and reports the results from recent clinical trials.
Journal ArticleDOI

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.

TL;DR: A 77-year-old male metastatic anorectal melanoma patient presenting with HPD over 2 months of a PD1 inhibitor treatment course is reported and this HPD blood phenotype is documented.